 |
 |
|
|
RESÚMENES SEPTIEMBRE 2006 |
Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal
para acceder al resúmen)
Substance misuse in first-episode psychosis:
15-month prospective follow-up study
D. Wade, S. Harrigan,
J. Edwards, P. M. Burgess, G. Whelan, P. D. McGorry
The British Journal of Psychiatry (2006) 189:
229-234
Untreated illness and outcome of psychosis
Mary Clarke, Peter Whitty, Stephen Browne, Orfhlaith
McTigue, Moayyad Kamali, Maurice Gervin, Anthony Kinsella, John L. Waddington, Conal
Larkin, Eadbhard O'Callaghan
The British Journal of Psychiatry (2006) 189:
235-240
Biological
models of schizophrenia: an update
F. Lotstra
L’Encephale. Vol 32 - N° 4 - Aout 2006: 446 - 451
Comparative evaluation of quality of life in
patients with schizophrenia treated with conventional versus atypical neuroleptics: results of a transversal study
F. Divanon, P. Delamillieure,
A. Lehaguez, T. Vasse,
R. Morello, R. Gourevitch,
S. Langlois, F. Assouly-Besse,
J.D. Guelfi, M. Petit, S. Dollfus
L’Encephale.
Vol 32 - N° 4 - Aout 2006:
459 - 465
Functional
Imaging as a Predictor of Schizophrenia
Heather C. Whalley, Enrico Simonotto, William
Moorhead, Andrew McIntosh, Ian Marshall, Klaus P. Ebmeier,
David G.C. Owens, Nigel H. Goddard, Eve C. Johnstone
and Stephen M. Lawrie
Biological Psychiatry. Volume 60, Issue 5, 1 September 2006, Pages 454-462
Neuropsychological
Performance in First-Episode Adolescents with Schizophrenia: A Comparison with
First-Episode Adults and Adolescent Control Subjects
Tonya White, Beng-Choon
Ho, Julianna Ward, Daniel O’Leary and Nancy C. Andreasen
Biological
Psychiatry. Volume 60, Issue 5, 1 September 2006, Pages 463-471
Prediction of Functional Outcome 18 Months After a First Psychotic Episode. A Proton Magnetic Resonance
Spectroscopy Study
Stephen J. Wood, Gregor E. Berger, Martin Lambert, Phillipe
Conus, Dennis Velakoulis,
Geoffrey W. Stuart, Patricia Desmond, Patrick D. McGorry,
Christos Pantelis
Arch Gen Psychiatry. 2006;63:969-976
Environment and Schizophrenia: Review: The
Wider Social Environment and Schizophrenia
Judith Allardyce
and Jane Boydell
Schizophrenia
Bulletin 2006 32(4):592-598
Predictors of Psychosis Remission in
Psychotic Disorders That Co-occur With Substance Use
Carol L. M. Caton,
Deborah S. Hasin, Patrick E. Shrout,
Robert E. Drake, Boanerges Dominguez, Sharon Samet and Bella Schanzer
Schizophrenia
Bulletin 2006 32(4):618-625
Clozapine
Use and Relapses of Substance Use Disorder Among
Patients With Co-occurring Schizophrenia and Substance Use Disorders
Mary F. Brunette, Robert E.
Drake, Haiyi Xie, Gregory
J. McHugo and Alan I. Green
Schizophrenia
Bulletin 2006 32(4):637-643
Psychotic Spectrum Disorders and Alcohol Abuse:
A Review of Pharmacotherapeutic Strategies and a
Report on the Effectiveness of Naltrexone and Disulfiram
Ismene L. Petrakis, Charla Nich
and Elizabeth Ralevski
Schizophrenia
Bulletin 2006 32(4):644-654
Randomized Controlled Trial of Effect of
Prescription of Clozapine Versus
Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia
Shôn W. Lewis, Thomas R. E. Barnes, Linda Davies, Robin M. Murray, Graham
Dunn, Karen P. Hayhurst, Alison Markwick,
Helen Lloyd and Peter B. Jones
Schizophrenia
Bulletin 2006 32(4):715-723
WHICH ANTIPSYCHOTIC: DO I CHOOSE NEXT?
Curr Psychiatr OnLine. Vol. 5, No. 9 /
September 2006
Reducing guesswork in
schizophrenia treatment. PANSS can target and gauge
therapy, predict outcomes
Curr Psych OnLine. Vol. 5, No. 9 / September 2006
Unawareness in schizophrenia: Neuropsychological and neuroanatomical
findings
LORENZO PIA, MARCO TAMIETTO
Psychiatry and Clinical Neurosciences. Volume
60 Page 531 - October 2006
Attention and Memory Deficits in Schizophrenia: The Role of Symptoms of
Depression
Moser, Christine; Krieg, Jurgen C; Zihl, Josef;
Lautenbacher, Stefan
Cognitive &
Behavioral Neurology. 19(3):150-156, September 2006
Levetiracetam in Tardive Dyskinesia
Meco, Giuseppe; Fabrizio, Edito; Epifanio, Antonio; Morgante,
Francesca; Valente, Marcella; Vanacore, Nicola; Di Rosa, Antonio E; Morgante,
Letterio
Clinical Neuropharmacology. 29(5):265-268, September/October 2006
Frontal
lobe volumes in schizophrenia: Effects of stage and duration of illness
Preethi Premkumar, Veena Kumari, Philip J.J. Corr and Tonmoy Sharma
Journal of Psychiatric Research. Volume 40, Issue 7, October 2006, Pages 627-637
Behavioral
inhibition system (BIS), Behavioral activation system (BAS) and schizophrenia:
Relationship with psychopathology and physiology
Marion R.M. Scholten, Jack
van Honk, André Aleman and René S. Kahn
Journal of Psychiatric Research. Volume 40, Issue 7, October 2006, Pages 638-645
Relation
between cerebrospinal fluid, gray matter and white matter changes in families
with schizophrenia
Thomas Schneider-Axmann,
Thomas Kamer, Manuel Moroni,
Nadja Maric, Ralf Tepest, Indra Dani,
William G. Honer, Harald Scherk, Marcella Rietschel,
Thomas G. Schulze, Daniel J. Müller, Joachim Cordes, Helmut Schönell, Helmuth Steinmetz, Wofgang Gaebel, Kai Vogeley, Kai-Uwe Kühn, Michael Wagner,
Wolfgang Maier, Frank Träber, Wolfgang Block, Hans H.
Schild and Peter Falkar
Journal of Psychiatric Research. Volume 40, Issue 7, October 2006, Pages 646-655
Psychiatric
comorbidity in first episode schizophrenia: A 2 year,
longitudinal outcome study
Kang Sim, Thiam Hee Chua, Yiong Huak Chan, Rathi Mahendran and Siow Ann Chong
Journal of Psychiatric Research. Volume 40, Issue 7, October 2006, Pages 656-663
Associations
between serum brain-derived neurotrophic factor
levels and clinical phenotypes in schizophrenia patients
Tiao-Lai Huang and Chien-Te Lee
Journal of Psychiatric Research. Volume 40, Issue 7, October 2006, Pages 664-668
Efficacy
of risperidone versus olanzapine
in patients with schizophrenia previously on chronic conventional antipsychotic
therapy: A switch study
Xiaohong Wang, Robert
Savage, Andrey Borisov, Jill
Rosenberg, Bobbi Woolwine, Melanie Tucker, Roberta
May, Jacqueline Feldman, Charles B. Nemeroff and
Andrew H. Miller
Journal of Psychiatric Research. Volume 40, Issue 7, October 2006, Pages 669-676
Risperidone augmentation of clozapine.
A critical review
Vassilis P. Kontaxakis,
Panayotis P. Ferentinos,
Beata J. Havaki-Kontaxaki,
Konstantinos G. Paplos,
Dimitra A. Pappa
and George N. Christodoulou
Intramuscular aripiprazole
for the treatment of acute agitation in patients with schizophrenia or
schizoaffective disorder: a double-blind, placebo-controlled comparison with
intramuscular haloperidol
Raisa Andrezina,
Richard C. Josiassen,
Ronald N. Marcus, Dan A. Oren, George Manos,
Elyse Stock, William H. Carson and Taro Iwamoto
Psychopharmacology. Volume 188, Number 3 / October, 2006: 281-292
Randomized, Double-blind 6-Month Comparison of Olanzapine
and Quetiapine in Patients With
Schizophrenia or Schizoaffective Disorder With Prominent Negative Symptoms and
Poor Functioning
Kinon, Bruce J; Noordsy, Douglas L; Liu-Seifert, Hong;
Gulliver, Angela H; Ascher-Svanum, Haya; Kollack-Walker, Sarah
Journal of Clinical
Psychopharmacology. 26(5):453-461,
October 2006
Effects of an Educational Intervention on Weight Gain in Patients Treated
With Antipsychotics
Mauri, Mauro; Castrogiovanni, Silvia; Simoncini, Marly; Iovieno, Nadia;
Miniati, Mario; Rossi, Andrea; Dell'Agnello, Grazia; Fagiolini, Andrea; Donda,
Pietro; Cassano, Giovanni Battista
Journal of Clinical
Psychopharmacology. 26(5):462-466,
October 2006
Efficacy of Topiramate, Valproate,
and Their Combination on Aggression/Agitation Behavior in Patients With Psychosis
Gobbi, Gabriella; Gaudreau, Pierre-Olivier; Leblanc,
Nancy
Journal of Clinical
Psychopharmacology. 26(5):467-473,
October 2006
Sex Selection Bias in Schizophrenia Antipsychotic Trials
Chaves, Ana Cristina; Seeman, Mary V
Journal of Clinical
Psychopharmacology. 26(5):489-494,
October 2006
Improvement of Sustained Attention and Visual and Movement Skills, but Not
Clinical Symptoms, After Dehydroepiandrosterone
Augmentation in Schizophrenia: A Randomized, Double-blind, Placebo-controlled,
Crossover Trial
Ritsner, Michael S; Gibel, Anatoly; Ratner,
Yael; Tsinovoy, German; Strous,
Rael D
Journal of Clinical
Psychopharmacology. 26(5):495-499,
October 2006
Association Between Antipsychotic-induced
Elevation of Liver Enzymes and Weight Gain: A Prospective Study
Rettenbacher, Maria A; Baumgartner, Susanne; Eder-Ischia, Ursula; Edlinger,
Monika; Graziadei, Ivo;
Hofer, Alex; Huber, Regina; Hummer, Martina; Kemmler,
Georg; Weiss, Elisabeth; Fleischhacker, W. Wolfgang
Journal of Clinical
Psychopharmacology. 26(5):500-503,
October 2006
The Early Effect of Olanzapine and Risperidone on Insulin Secretion in Atypical-naive
Schizophrenic Patients
Chiu, Chih-Chiang; Chen, Kun-Po; Liu, Hui-Ching; Lu, Mong-Liang
Journal of Clinical
Psychopharmacology. 26(5):504-507,
October 2006
Schizoaffective
disorders are psychotic mood disorders; there are no schizoaffective disorders
C.
Psychiatry Research. Volume 143, Issues 2-3, 30 August 2006, Pages 255-287
A
pilot study of facial, cranial and brain MRI morphometry
in men with schizophrenia: Part 2
Karin Maria Henriksson,
Karin Wickstrom, Nils Maltesson,
Anders Ericsson, Johan Karlsson, Finn Lindgren, Kalle Astrom, Thomas Farrell
McNeil and Ingrid Agartz
Psychiatry Research: Neuroimaging.
Volume 147,
Issues 2-3, 30 October 2006, Pages 187-195
The Relationship Between
Quality of Life and Clinical Efficacy From a Randomized Trial Comparing Olanzapine and Ziprasidone
Glenn A.
Phillips, David L. Van Brunt, Suraja M. Roychowdhury, Wen Xu, and Dieter Naber
J Clin
Psychiatry 2006;67:1397-1403
Galantamine Improves Cognition in Schizophrenic
Patients Stabilized on Risperidone
Max H. Schubert, Keith A. Young and Paul B. Hicks
Biological Psychiatry. Volume 60, Issue 6, 15 September 2006, Pages 530-533
Glycine Transporter I Inhibitor, N-methylglycine
(Sarcosine), Added to Clozapine
for the Treatment of Schizophrenia
Biological Psychiatry. Volume 60, Issue 6, 15 September 2006, Pages 645-649
Ziprasidone-induced cognitive enhancement in
schizophrenia: Specificity or pseudospecificity?
Anil K. Malhotra,
Katherine E. Burdick, Kamran Razi,
John A. Bates, Michael Sanders and John M. Kane
Schizophrenia Research. Volume 87, Issues 1-3, October 2006, Pages 181-184
Neurocognitive performance and negative symptoms: Are they
equal in explaining disability in schizophrenia outpatients?
Victoria Villalta-Gil, Míriam Vilaplana, Susana Ochoa, Josep Maria Haro, Montserrat Dolz, Judit Usall, Jorge Cervilla and NEDENA
Group
Schizophrenia Research. Volume 87, Issues 1-3, October 2006, Pages 246-253
Classification
of adolescent psychotic disorders using linear discriminant
analysis
Patricia J. Pardo, Apostolos P. Georgopoulos, John T. Kenny, Traci A. Stuve, Robert L. Findlingi
and S. Charles SchulzSchizophrenia Research. Volume 87, Issues 1-3, October 2006, Pages
297-306
Schizophrenia Research. Volume 87, Issues 1-3, October 2006, Pages
307-315
JINGPING ZHAO, XIAOLIN HE, ZHENING
LIU, DESEN YANG
The International Journal of Psychiatry in Medicine.
Volume 36, Number 2 / 2006:
171 - 181